title: Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.
abstract: Liver disease secondary to hepatitis C virus (HCV) infection is a rising cause of morbidity and mortality among individuals who have been infected parenterally with human immunodeficiency virus (HIV) such as injection drug users, hemophiliacs, and transfused patients. We analyzed both the efficacy of interferon (IFN) alpha therapy in these patients and the predictors of response to this agent. A total of 119 patients with chronic hepatitis C (90 of whom were infected with HIV and 29 of whom were not) were included in a multicenter, prospective, open, nonrandomized observational study. IFN-alpha was given subcutaneously in a dosage of 5 million units three times a week during a 3-month period; those patients who responded received a dose of 3 million units given subcutaneously three times a week for an additional 9 months. One hundred seven patients completed the study; the level of aminotransferases returned to normal and sera became negative (complete response) for HCV RNA in 26 (32.5%) of 80 HIV-infected patients and 10 (37.0%) of 27 non-HIV-infected patients (P = .666) after completion of the treatment. Two variables were independently associated with a response in HIV-infected patients: a CD4+ T lymphocyte count of > 500 x 10(6)/L and a baseline HCV viremia level of < 10(7) copies/mL. In the 12 months following treatment, relapses occurred in 30.8% of the HIV-infected patients and 12.5% of non-HIV-infected patients (P = .403).
authors.affiliation: Centro de Investigación Clinica, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: V
authors.initials: V
authors.lastname: Soriano
authors.forename: J
authors.initials: J
authors.lastname: García-Samaniego
authors.forename: R
authors.initials: R
authors.lastname: Bravo
authors.forename: J
authors.initials: J
authors.lastname: González
authors.forename: A
authors.initials: A
authors.lastname: Castro
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.forename: P
authors.initials: P
authors.lastname: Martínez-Odriozola
authors.forename: M
authors.initials: M
authors.lastname: Colmenero
authors.forename: E
authors.initials: E
authors.lastname: Carballo
authors.forename: D
authors.initials: D
authors.lastname: Suárez
authors.forename: F J
authors.initials: FJ
authors.lastname: Rodríguez-Piñero
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: J
authors.initials: J
authors.lastname: del Romero
authors.forename: J
authors.initials: J
authors.lastname: Pedreira
authors.forename: J
authors.initials: J
authors.lastname: González-Lahoz
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications*; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D000410:Alanine Transaminase